Breast Cancer Clinical Trial

Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer

Summary

Genes are the "blueprints" for our bodies. Some people are born with an abnormal copy ("mutation") of a gene. These people may have a higher chance of getting a disease. Different mutations in different genes cause different diseases. Some women get breast cancer because they are born with an abnormal copy of a gene called BRCA1 or BRCA2. These women also have a higher chance of getting ovary cancer. Women with breast cancer and an abnormal copy of BRCA1 or BRCA2 also have a higher chance of getting a second breast cancer in their other breast. Because of this, women who might have a mutation may have genetic testing soon after their breast cancer diagnosis to learn about their risks of getting another cancer.

Genetic testing may be done right after a woman has been diagnosed with breast cancer. It may also be done later, after surgery is done to treat the cancer. The investigators do not know when it is best to do genetic testing. The investigators are doing this study to try to understand whether women prefer testing before or after surgery. The investigator also want to find out how they feel about their choice later on, when their diagnosis in more in their past.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of invasive breast cancer or DCIS
Appropriate for genetic testing, defined as if they meeting one or more of the following criteria (note that patients may be appropriate for genetic testing even if they do not meet these criteria, but NCCN and most payers recognize these groups as clearly appropriate for testing)
Must be a primary malignancy (not recurrence), but can be second diagnosis if is a contralateral cancer and the first cancer was not treated with mastectomy
Female age ≥18,
If Ashkenazi Jewish: Breast cancer diagnosis ≤ 60. Subjects will be presumed to be of Ashkenazi ethnicity if Jewish religious preference is confirmed in subject and at least 1 parent, unless they explicitly endorse Sephardic, Iranian, Yemeni/Ethiopian, or Bukharan Jewish Decent, in which case non-Ashkenazi criteria will be applied.

If not Ashkenazi Jewish:

Breast cancer diagnosis ≤ 45 OR
Bilateral breast cancer, with first diagnosed ≤ 50 OR
Breast cancer diagnosed at any age with a male relative with breast cancer OR

Breast cancer diagnosis ≤ 50 with one or more of the following::

1 or more relative with breast cancer ≤ 50 or
1 or more relative with ovarian cancer
Have not completed definitive surgical treatment
For patients planning mastectomy for treatment, has not yet undergone mastectomy
For patients planning breast conservation for treatment, has not yet begun adjuvant radiation therapy

Exclusion Criteria:

LCIS without invasive cancer (IDC or ILC) and without DCIS
Previous breast cancer treated with mastectomy
Plan for neoadjuvant chemotherapy before surgery
Unable to complete English language questionnaires, as instruments have not been validated in non-English speaking populations

Study is for people with:

Breast Cancer

Estimated Enrollment:

108

Study ID:

NCT01386411

Recruitment Status:

Completed

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

108

Study ID:

NCT01386411

Recruitment Status:

Completed

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider